Biophytis Stock Forecast, Price & News

-0.56 (-4.41 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $12.14
50-Day Range
MA: $14.51
52-Week Range
Now: $12.14
Volume512 shs
Average Volume19,701 shs
Market Capitalization$137.34 million
P/E RatioN/A
Dividend YieldN/A
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.
Biophytis logo

Industry, Sector and Symbol

Industry --
Current SymbolNASDAQ:BPTS
Phone33 1 44 27 23 00
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$137.34 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

-- Sector

89th out of 267 stocks

-- Industry

90th out of 269 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.56 (-4.41 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BPTS News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Biophytis (NASDAQ:BPTS) Frequently Asked Questions

What stocks does MarketBeat like better than Biophytis?

Wall Street analysts have given Biophytis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biophytis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Biophytis' key executives?

Biophytis' management team includes the following people:
  • Mr. Stanislas Veillet, Chairman & CEO (Age 55, Pay $446.95k)
  • Ms. Evelyne Nguyen, Chief Financial Officer (Age 59)
  • Mr. Waly Dioh, Chief Operating Officer (Age 52)
  • Dr. Pierre J. Dilda, Chief Scientific Officer (Age 51)
  • Dr. Rene Lafont, Scientific Advisor & Member of Scientific Advisory Board (Age 75)
  • Dr. Samuel Agus, Chief Medical Officer (Age 53)
  • Ms. _ Teylan, Financial Controller

Who are some of Biophytis' key competitors?

When did Biophytis IPO?

(BPTS) raised $20 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,200,000 shares at a price of $15.00-$18.00 per share. H.C. Wainwright acted as the underwriter for the IPO.

What is Biophytis' stock symbol?

Biophytis trades on the NASDAQ under the ticker symbol "BPTS."

When does the company's lock-up period expire?

Biophytis' lock-up period expires on Monday, August 9th. Biophytis had issued 1,200,000 shares in its initial public offering on February 10th. The total size of the offering was $20,100,000 based on an initial share price of $16.75. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Biophytis?

Shares of BPTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biophytis' stock price today?

One share of BPTS stock can currently be purchased for approximately $12.14.

How much money does Biophytis make?

Biophytis has a market capitalization of $137.34 million.

How many employees does Biophytis have?

Biophytis employs 25 workers across the globe.

What is Biophytis' official website?

The official website for Biophytis is

How can I contact Biophytis?

The company can be reached via phone at 33 1 44 27 23 00.

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.